![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Low rate of danoprevir resistance with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a/ribavirin (P/R) in HCV G1b-infected treatment-naive and treatment-experienced patients
|
|
|
Reported by Jules Levin
APASL 2013 Singapore June 6-10
S. Le Pogam,1 L. Li,1 M.T. Navarro,2 J. Zhou,3 A. Voulgari,4 N.S. Shulman,2 K. Klumpp,1 I. Najera1
1Hoffmann-La Roche Inc, Nutley, NJ, USA; 2Genentech, South San Francisco, CA, USA; 3Roche Product Development - Asia Pacific, Shanghai, China; 4Roche Products Ltd, Welwyn, UK
APASL: High SVR24 rates with ritonavir-boosted danoprevir (DNVr) plus PegIFN alfa-2a/ribavirin (P/R) in HCV genotype (G)1/4-infected treatment-naive patients: the DAUPHINE study - (06/09/13)
3 & 4 Oral IFN-Free Roche HCV Regimens Studies, Treatment Naïve or Null Responders: setrobuvir+mericitabine+danoprevir/r+rbv. ANNAPURNA Study
http://www.natap.org/2012/HCV/090412_01.htm
![APASL1.gif](../images/061913/061913-9/APASL1.gif)
![APASL2.gif](../images/061913/061913-9/APASL2.gif)
![APASL3.gif](../images/061913/061913-9/APASL3.gif)
![APASL4.gif](../images/061913/061913-9/APASL4.gif)
![APASL5.gif](../images/061913/061913-9/APASL5.gif)
![APASL6.gif](../images/061913/061913-9/APASL6.gif)
![APASL7.gif](../images/061913/061913-9/APASL7.gif)
![APASL8.gif](../images/061913/061913-9/APASL8.gif)
![APASL9.gif](../images/061913/061913-9/APASL9.gif)
![APASL10.gif](../images/061913/061913-9/APASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|